Page last updated: 2024-10-29

ifosfamide and Diffuse Parenchymal Lung Disease

ifosfamide has been researched along with Diffuse Parenchymal Lung Disease in 1 studies

Research Excerpts

ExcerptRelevanceReference
"Ifosfamide is an active alkylating agent used in the first-line treatment of NSCLC."2.71Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. ( Chen, MC; Chen, YM; Lee, CS; Lin, WC; Perng, RP; Shih, JF; Tsai, CM, 2003)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, YM1
Shih, JF1
Lee, CS1
Chen, MC1
Lin, WC1
Tsai, CM1
Perng, RP1

Trials

1 trial available for ifosfamide and Diffuse Parenchymal Lung Disease

ArticleYear
Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
    Lung cancer (Amsterdam, Netherlands), 2003, Volume: 39, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2003